Scholar Rock is trading 4.45% higher at $50.30 after JPMorgan raised its price target to $70 from $63 while maintaining an Overweight rating on September 21.

  • The target change followed ISEMBYLD’s recent FDA approval and launch outlook.
  • The available report does not explicitly attribute the September 22 move to the target change, while broader indices are only modestly higher.